LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.

Studied

A 12-week randomized, double-blind phase 1b trial in adults with type 2 diabetes compared ascending retatrutide doses with placebo and dulaglutide. Safety and tolerability were primary outcomes; glucose, weight and drug-processing measures were secondary.

Who / model

72 participants received treatment across retatrutide groups, placebo (15 participants) and dulaglutide (five participants).

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Adverse events affected 63% with retatrutide, 60% with dulaglutide and 54% with placebo; gastrointestinal problems were most common. In the three highest retatrutide groups, HbA1c fell 1·2–1·6 percentage points more than placebo. The highest group lost 8·96 kg more than placebo.

Limits

No author-stated limitations were available in the abstract. Of 72 treated participants, 29 discontinued prematurely.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary